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This review provides the rationale for integrating genomic and protein biomarkers in the evolving diagnosis and
management of dilated cardiomyopathy (DCM) and its causal pathway to heart failure (HF), with a larger objec-
tive to serve as a template for genomic and phenomic profiling of other cardiovascular disease. DCM is a major
cause of HF and accounts for more than half of heart transplantation in adults and children worldwide. DCM
may remain asymptomatic for years, but HF and/or arrhythmias, both late manifestations of the disease, ulti-
mately cause significant morbidity and mortality. A significant proportion of DCM has a genetic etiology. DCM
can also result from environmental injury such as infection, toxins, or catecholamine excess. While molecular
genetic testing can identify those at risk for genetic DCM, epigenetic and sentinel phenomic staging can help to
identify those at highest risk in need for intervention. Phenomic staging includes integrating clinical and imaging
features, transcriptomics, higher order proteomics and metabolomics interactions, and epidemiological data.
This principle can be applied in family members of patients with DCM, where genetic testing and clinical pheno-
typing are indicated. This will allow the design of specific interventions tailored to individuals sharing similar
risks, to alter the natural history of DCM and obviate complications such as HF/arrhythmias. (J Am Coll Cardiol
2012;60:283–9) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.005Cardiovascular disease occurs as a cumulative consequence
of the host’s inadequate repertoire, often genetic, to respond
to stress or injury. Symptoms typically occur late as a
manifestation of failure of compensation. The intermediate
stages of disease progression, including inflammation, growth,
apoptosis, or autophagy, directly lead to tissue remodeling.
This stage is often clinically silent, but offers the optimal
opportunity for intervention. Common examples include
the atherosclerotic plaque in coronary disease, asymptomatic
left ventricular systolic dysfunction, or atrial remodeling
prior to symptomatic fibrillation.
This review aims to apply current concepts of genomics
and phenomics to the paradigm of dilated cardiomyopathy
(DCM) and its progression to heart failure (HF). This
includes genetic predisposition, imaging, and proteomics to
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DCM, a disease of the myocardium, is defined by left
ventricular enlargement and systolic dysfunction. In familial
studies, DCM may be asymptomatic for years (1). Eventual
symptoms include HF, arrhythmias or sudden death, or
embolus from left ventricular thrombus. In contrast, HF is
a symptom complex in which heart function is inadequate to
meet physiological demands without presumption of etiology or
systolic function.
Phenome, Genome, and Epigenome
Variation in the genetic repertoire (genome), together with
the biological consequences and interactions with the envi-
ronment, lead to molecular, biochemical, physiological, and
clinical manifestations (phenome). We define the phenome
here as the high-dimensional phenotype data for the entire
organism (2), including not only clinical characteristics, but
also information from cells, tissues, organs, and individuals
(including epidemiological data), ranging from gene expres-
sion (transcriptomics), gene networks (integrative genomics
[3]), and higher order proteomics and metabolomics inter-
actions (2). The study of “genomics” in this context means
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variants, both common and rare
as well as single nucleotide changes
or larger structural (copy number
variant) changes, and understand-
ing the total impact of gene vari-
ants on the phenome. Thus, the
phenome integrates higher order
interactions or systems biological
networks (4) to better define tran-
sitional programs to disease.
Epigenetics defines the inter-
section of the genome, without
changes to its nucleotide se-
quence, with the environment
that leads to phenomic variations. Epigenetic mechanisms
most commonly include methylation, acetylation, or ni-
trosylation patterns of modifications of gene function. Such
epigenetic changes may be heritable, and the global changes
are incorporated in the epigenome. An isogenic murine line
ith validated identical deoxyribonucleic acid (DNA) se-
uence can exhibit significantly different phenotypes due to
ifferences in epigenetic modifications (Fig. 1) (5). Other
examples include the paternally or maternally inherited
predisposition to diabetes or post-natal cardiovascular risk
from maternal intrauterine conditions (6).
DCM and Its Relationship to HF:
Phenomics and Genomics Considerations
DCM, when applied without inference to any specific
etiology, commonly presents with few phenotypic features
that enable differentiating its etiology. Despite the well-
established value (7) and now guideline-mandated use of
family history as a means to detect genetically based DCM
(8) because of familial clustering with Mendelian disease,
family history alone is insensitive to detect familial DCM,
even when ischemic and other detectable etiologies (aside
from genetic) have been ruled out (commonly termed
idiopathic dilated cardiomyopathy [IDC]). This is because
asymptomatic systolic dysfunction, left ventricular enlarge-
ment, or DCM may be present for years with symptoms
occurring only late in the causal pathway from (Fig. 2) (9).
In addition, the age of onset of DCM varies widely, and
ranged from 0 to 75 years in a familial DCM cohort from
our group (10). Thus, even in family members genetically at
risk to carry a DCM mutation, their DCM may not have yet
presented and can only be identified with prospective
clinical screening. Family history alone was found to detect
5% of familial disease (11), while clinical screening of
relatives has been shown to detect familial DCM in 20%
(11) to 48% of cases (see Burkett and Hershberger for
review [1]). Combining family history with clinical
screening of relatives, and emphasizing echocardiography
to assess LV size and function, is essential to identify
Abbreviations
and acronyms
BNP  brain natriuretic
peptide
DCM  dilated
cardiomyopathy
GWAS  genome-wide
association studies
HF  heart failure
IDC  idiopathic dilated
cardiomyopathy
MMP  matrix
metalloproteinasefamilial DCM (1,8).DCM Genomics:
Rare and Common Coding Variants
Most classical Mendelian disease is characterized by familial
clustering of the phenotype of interest with a discernible
pattern of inheritance, commonly resulting from very rare
variants (e.g., 0.1% allele frequency) in coding sequence,
thereby to change amino acids (termed nonsynonymous),
invoke stop codons, alter splicing, or cause reading frames to
shift (12). However, sequencing of genetic DCM has shown
that the coexistence of multiple rare variants may also cause
DCM (13,14).
Based on family studies, rare nonsynonymous mutations
from 30 genes have been reported to cause nonsyndromic
DCM (i.e., isolated DCM not associated with extra cardiac
disease; lists of genes are available that cause syndromic DCM
[9,15] or mixed phenotypes [e.g., arrhythmogenic right ven-
tricular cardiomyopathy (16)]), even though they account for
only 45% to 50% of genetic DCM (12,15,17,18). The
fractional contribution of each gene to DCM varies signif-
icantly: truncating variants in TTN, encoding titin, ac-
counted for up to 25% of familial DCM (18), although most
DCM genes have been shown to have much lower frequen-
cies (e.g., LMNA 6%; MYH7 4%, MYBPC3 4%, TNNT2
3%, MYH6 3%, SCN5A 3%) (12). Most mutations are very
rare or novel (19) and are usually specific to 1 individual or
family (a “private” mutation). This makes both diagnostic
and discovery approaches challenging, as it can be difficult to
determine the true contribution of a newly identified variant
to disease (12).
The gene ontology for DCM is shown (Table 1), with
numerous genes encoding sarcomeric, z-disk, or cytoskeletal
proteins. However, rare DCM mutations have also been
Figure 1 Epigenetic Regulation of Coat Color
These 6 mice have identical genomic DNA, as they are littermates from an
isogenic line maintained by brother-sister matings for over 30 generations. The
difference in coat color reflects variable expressivity of a cryptic promoter
upstream from the coat color locus, a manifestation of a transcriptionally active
retrotransposon that is epigenetically but variably reset during embryogenesis in
each mouse. Adapted, with permission, from Whitelaw and Martin (5).
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other than these such as LMNA, which encodes a protein of
the inner nuclear lamina, and others. Collectively these data
indicate that DCM, a “final phenotype” (9), results from
diverse genomic or phenomic insults via activation of diverse
DCM disease-causing cascades.
In contrast to familial DCM, no large systematic studies
have been undertaken to examine the genomic basis of sporadic
IDC. In our resequencing studies of 11 known DCM genes
(20,21) in 312 probands with either sporadic or familial DCM
of unknown cause, we observed similar frequencies of possibly
or likely disease-causing rare variants. While familial DCM is
considered to have a genomic basis (22), whether IDC is
principally a genomic disease remains an open question.
Common or complex disease, in contrast to rare variant
disease, has been thought to result from the cumulative
effect of low penetrance variants that are frequently found in
the general population (e.g., usually 5% allele frequency)
(23). The first genome-wide association study (GWAS) of
common variants in 1,179 DCM patients (24) found 2
single-nucleotide polymorphisms, 1 in BAG3, a gene previ-
ously identified as having rare nonsynonymous variants
causing DCM (25). BAG3, as a co-chaperone of heat shock
proteins, targets misfolded cellular proteins for recycling via
Figure 2 Disease Model: DCM and HF
This figure portrays dilated cardiomyopathy (DCM) and heart failure (HF) as sep-
arate entities. The causative hit, depicted by a thick blue arrow, includes
genetic cause, depicted here as 1 high-probability Mendelian mutation
although other genomic models are possible, if not likely (9,12). The causal
pathways from normal heart to DCM and from DCM to HF are shown by the
2 other blue arrows. The causal pathway to DCM may take years and is
asymptomatic until very late in its causal pathway when HF, arrhythmia, or
embolus (from mural thrombus) present. Because of the biological complexity
and epidemiological impact of HF, its causal pathway from DCM is shown,
although pathways from DCM to arrhythmia and embolus are also relevant.
Factors that may accelerate these causal pathways are depicted with green
arrows for DCM (A) or HF (B); environmental examples include hypertension
and alcohol use, while genomic factors include unfavorable genotypes (risk
alleles). Other factors that may delay or arrest progression to DCM or HF are
shown in red (C, D); such factors could include favorable environmental factors
(e.g., good nutrition, a low-salt diet, low blood pressure, drug therapy with
angiotensin-converting enzyme inhibitors or beta-blockers, genomic factors such
as a protective alleles). Acute HF (e.g., from a large anterior wall myocardial infarc-
tion) is shown with a dotted line (E); in this situation the acute onset of HF may
cause DCM subacutely, although the degree that genomics plays a role in DCM
resulting from acute HF is uncertain, as most studies have focused on chronic HF.
Also, whether chronic HF modulates or exacerbates the DCM causal pathway (F)
itself remains poorly defined. The disordered HF physiology also feeds back onto
itself, the so-called vicious cycle of HF (G).selective autophagy, and thus may be a pathway for causa-tion or risk whereby if protein quality control is compro-
mised, then cardiomyopathy can result. No additional
DCM GWAS have been published, although an earlier
pilot association study of 6 resequenced genes suggested that
a common variant approach may be fruitful (26), and a
peripartum cardiomyopathy GWAS reported a locus on
chromosome 12 (27). An HF GWAS has recently been
reported (28).
Large-scale genome-wide searches for genomic variation
aside from a GWAS (24) have not been reported in DCM.
Three single-gene studies have identified structural variants
causing DCM (in EYA4 [29], LMNA [30], and BAG3
25]), but to date no genome-wide evaluation of structural
ariants in a large DCM cohort has been reported. Further,
ystematic evaluation of 5’- and 3’-untranslated regions,
romoter variants, noncoding ribonucleic acids (RNAs),
pigenetic impact, or other genomic variation in a large scale
tudy of DCM has not been reported.
here Genomic and
cquired Forms of DCM Meet
CM is commonly categorized clinically as “ischemic” or
nonischemic,” where nonischemic DCM includes IDC, a
iagnosis of exclusion of readily detectable causes. Acquired
orms of nonischemic DCM exist, and include toxins (e.g.,
nthracyclines), infiltrative processes, longstanding mechan-
cal load from valvular or congenital causes, viral infection
e.g., coxsackievirus or parvovirus), nonviral infection (e.g.,
rypanosoma cruzii in Chagas disease), nutritional deficien-
ies, or a variety of inflammatory processes (9,17,31).
hether any of these environmental factors contribute to
enetic DCM risk, and vice versa, the degree that genetic
ackground modulates environmental risk remains an active
esearch area. However, global processes such as ischemia,
itochondrial dysfunction, and chronic tachyarrhythmias
17) may all directly influence the genome to increase the
isk for DCM and eventually HF (Fig. 3).
DCM Gene OntologyTable 1 DCM Gene Ontology
Sarcome Cytoskeleton Z-disc Nuclear envelope
ACTC1 DMD TCAP LMNA
MYH7 DES CSRP3 TMPO
MYH6 LDB3 ACTN2 Gamma secretase activity
MYBPC3 SGCD MYPN PSEN1
TNNT2 PDLIM3 ANKRD1 PSEN2
TNNC1 VCL NEBL Transcription factor
TNNI3 RYAB NEXN EYA4
TPM1 ILK RNA binding
TTN LAMA4 RBM20
Ion channel Mitochondrial Co-chaperone, heat shock
proteinsABCC9 TAZ/G4.5
SCN5A Sarcoplasmic
reticulum
BAG3
PLNDCM  dilated cardiomyopathy.
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etiological agent for human myocarditis. Coxsackievirus in
the host can produce an enteroviral protease 2A that can
cleave the dystrophin complex in the myocyte, resembling
the phenotype seen in patients with a genetic deficiency of
dystrophin (32). Furthermore, murine dystrophin dysfunc-
tion facilitates the release of virus from infected cells (33)
and pre-existing cardiomyopathy up regulates the coxsackie-
adenoviral receptor to facilitate viral entry (34). This illus-
trates a cooperative feedback system to facilitate the devel-
opment of DCM (35).
Evolution of DCM to HF
Regardless of cause, whether genomic, environmental, or
both, the underlying mechanisms leading from DCM to
HF involve multiple staged processes (Fig. 2). The progres-
sion from DCM to HF may start with major perturbations
of cytoskeletal-sarcomeric stability leading to contractile
inefficiencies cumulative in time, followed by metabolic
dysregulation, progressive cell death, cardiac remodeling,
inflammatory activation, and fibrosis (17,36). This com-
monly leads to progressive cardiac dilatation involving both
left- and right-sided chambers; and eventually, to death
from advanced HF or arrhythmia. While we consider DCM
to be one principal cause of HF, considerable clinical and
basic data support the concept of multiple overlapping
feedback loops shared by different etiologies (Fig. 2). Once
the HF cascade has been activated, multiple factors may
accelerate the causal pathways. Despite a potential genomic
Figure 3 Contribution of Genomic and Environmental
Factors to Adverse Myocardial Remodeling and DCM
The spectrum of conditions in dilated cardiomyopathy (DCM) and heart failure
is the product of gene and environment interaction. Most conditions are nei-
ther solely of genomic or environmental causes, but contains a differential
contribution of each. Conditions such as autosomal dominant dilated cardiomy-
opathy have a major genetic component, but whether an individual with a DCM
mutation will manifest the full disease phenome is dependent on the contribut-
ing environmental factors such as blood pressure, infections, or other risk fac-
tors. Conversely, patients with an environmentally induced DCM such as a
chemotherapy-induced cardiomyopathy have different thresholds of cardiac dys-
function, all of which is likely in part genetically determined. PCI  percutane-
ous coronary intervention.etiology for DCM, its progression and responsiveness totreatment may vary depending on the molecular network
involved. This underscores the opportunities of combining
genetic risk evaluation with biomarkers specific for pathway
activation as an integrated analysis for risk stratification,
pathway classification, and tailoring of intervention.
In addition, patients with DCM, whether from princi-
pally genomic or acquired factors or components of both,
may also harbor risk alleles (rare or common variants of
variable penetrance) that in combination predispose the
patient toward more aggressive cardiac remodeling (9).
Measuring Environmental Imprints
Reflected by Systems Biology Markers
and Imaging Phenotypes
While the nucleotide sequence of an individual’s genome is
generally stable, gene expression depends on the interactions
with the environment and epigenetic influences (e.g., the
state of DNA methylation, acetylation, impact of micro-
RNAs) all part of the epigenome. The transcriptome is the
unique set of genes expressed or transcribed under such
specific conditions. Indeed recent data suggest that tran-
scriptomic signatures can be used in prognosticating pa-
tients with new onset HF (37). The resulting diversity of
proteins produced by a cell or organ can now be character-
ized by high throughput gel electrophoresis or mass spec-
trometry as the proteome, and the metabolic processing
profiles determined by mass spectrometry, the metabolome
(38). Finally, the ultimate product of genetic and environ-
ment interaction that determines the protein-protein inter-
actions that direct measurable structural, signaling, func-
tional, and remodeling parameters contributes to the
phenome. These parameters will rapidly progress when
environmental influences on the genetic repertoire create
further stress, abnormal protein production and accumula-
tion, and ultimately structural instability and dysfunction of
the heart chambers (Fig. 4). These processes generally will
be very advanced before symptoms occur.
Common imaging tools that are useful for patients with
DCM include ultrasound or magnetic resonance imaging to
assess cardiac dimensions, systolic and diastolic function,
and evolving tissue characterization. Positron emission to-
mography and to a lesser extent, conventional radioisotope
imaging, can delineate the metabolic activities in the heart,
and differentiate areas of viability from areas of scar.
Protein Markers of DCM
Proteomic analysis can currently examine all the proteins
produced by the heart in detail (e.g., membrane, cytosol,
microsomal, or nuclear fractions) down to the fentomolar
level (39). This approach has allowed identification of
alterations in key proteomic pathways in DCM, and com-
plements well other genomic and systems biology tech-
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their cellular location and function provide not only biolog-
ical insights, but also are candidates for diagnostic biomark-
ers and potential therapeutic targets (40). For example, analysis
of the phospholamban mutation in human and mouse identi-
fied major alterations in endoplasmic reticulum stress, cal-
ium signaling pathways, cytoskeletal transitions, and acti-
ation of stress-inflammatory-apoptotic programs (36).
While protein biomarker candidates are numerous in this
ost-systems biology era, only a handful have been validated to
nter clinical decision making. The validated protein markers
n DCM and HF to date include those that provide informa-
ion on stress (natriuretic peptides, ST2), cell deaths or turn-
ver (hsTroponin), collagen turnover (PIIINP or CITP), and
atrix dynamics (serum matrix metalloproteinases [sMMPs]
nd possibly Galectin-3), among others. These markers appear
t different time points in the natural history of DCM evolving
o HF, conferring differential advantages for early detection,
rognosis, or therapeutic targeting.
Both brain natriuretic peptide (BNP) and ST2 appear to
eflect ventricular stress, and can be used to predict risk of
ecompensation. There is substantial experience with natri-
retic peptides in DCM as well as in HF (41). BNP or
roBNP levels increase the accuracy of diagnosis of HF in
he emergency department (42), and is cost-effective
43,44). Encouraging data also suggest that BNP can be
sed to prognosticate patients at the time of hospital
ischarge and to help assess targets for therapy in HF (45).
ST2 is a member of interleukin-1 receptor family, is
Figure 4
The Role of Biomarkers Reflecting Disease
Phenotype and the Interplay of Genetic and
Environmental Factors During Disease Progression
A variety of biomarkers (including genetic, protein, and imaging) can be
deployed to delineate disease progression in dilated cardiomyopathy. Genetic
biomarkers can identify an individual’s genetic predisposition. It is, however,
the environmental imprints on the genetic background that produces abnormal
unique proteins that foster disease progression in the susceptible individual.
The latter can be detected as proteomic or metabolomic markers. As the dis-
ease progresses further in the susceptible individual, cardiac structural and
functional alterations can be detected through imaging technologies. All of this
can take place before the onset of symptoms, thus setting the stage for early
intervention.ecreted by cultured monocytes subjected to mechanical ntress, and is induced and released by stretched cardiomyo-
ytes (46). In patients with HF, an increased ST2 level is an
ndependent predictor of death and need for heart trans-
lantation, beyond BNP (47). In the PRIDE (N-terminal
roBNP Investigation of Dyspnea in the Emergency De-
artment) study, Januzzi, Jr. et al. (47) showed that ST2
evels were useful in diagnosing acute HF in comparison
ith N-terminal proBNP, and were strongly predictive of
ortality at 1 year, particularly elevated in patients with
ystolic HF (48). ST2 has just been approved by the Food
nd Drug Administration for clinical use.
Modest elevations of the myofibrillar proteins troponins
and I in the serum have been found to be sensitive
arkers of myocyte injury in patients with HF without
schemic heart disease (49). Both cardiac troponin I and T
re markers of poor prognosis and independent predictors of
eath (50). The recently available high-sensitivity troponin
s detectable in 92% of HF patients (51), in contrast to the
raditional troponin being detectable in only 10%. Impres-
ively, the high-sensitivity troponin predicts early onset HF
nd increased mortality in the longitudinal Cardiovascular
ealth Study cohort study in asymptomatic patients over
decade of follow-up (52) and is probably important for
ntermediate follow-up, but it is not related to etiology
f HF.
Progressive cardiac dilation also involves matrix remod-
ling and increased collagen turnover. The level of plasma
rocollagen type III in patients with HF is an independent
redictor of adverse outcomes (53). There is also a correla-
ion between the propeptide serum collagen type I and
egree of myocardial fibrosis on biopsies taken from patients
ith hypertension (54). Similarly soluble MMPs such as
MMP9 also correlated with cardiac dilatation and a fall in
jection fraction (55). Plasma MMP-2, -7, -8, and -9 are
levated in the pediatric patients with DCM in comparison
ith healthy controls.
Recently approved galactin-3 is a protein produced by
ctivated macrophages under stress, for which plasma levels
ave been reported to predict adverse outcomes in patients
ith HF and can provide prognostic stratification for both
ystolic and nonsystolic HF (56). It has also been shown
hat the combination of galectin-3 with N-terminal
roBNP was the best predictor for prognosis in subjects
ith acute HF (56). Some of the novel biomarkers have
otential utility in helping tailor therapy in acute HF. For
xample, early data for endoglin indicate that it may be
seful as a noninvasive measure of left ventricular end-
iastolic pressure and its levels decrease with diuresis,
otentially providing an opportunity to titrate volume re-
oval (57). Neutrophil gelatinase–associated lipocalin is
seful as an early marker of worsening renal function, which
an be helpful in determining timing and aggressiveness of
iuresis (58,59).
Fc(gamma) receptors IIa on cardiomyocytes have poten-
ial functional importance in DCM, and contribute to the
egative inotropic effects of autoantibodies (60).
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Proteomic Markers Into DCM Management
The combination of genomic and proteomic markers can
help in our understanding the human DCM refocusing to
earlier at-risk asymptomatic stages where better categoriza-
tion and risk stratification can help with personalized risk
management. The combinatorial genetic, proteomic, and
image phenotyping tools also help to devise tailored inter-
vention strategies according to genetic categories and host
response patterns. Attempts to characterize different types
of cardiomyopathy in advanced state have proven to be
challenging, as there are more similarities than differences at
that stage (35). End-stage ischemic and nonischemic car-
diomyopathies share many molecular and cellular pathways
in common, with only small differences in transcriptome
(61). The earlier intervention thus followed may have much
more impact on the natural history of the disease and prove
cost-effective in the long run.
This approach will be most valuable for family members
of affected probands with DCM, where patients with
inherited genetic risk can be better risk stratified by imaging
and protein markers to determine the appropriateness and
intensity for intervention at an early stage.
Summary
The rationale for more comprehensive genomic and phe-
nomic knowledge of DCM and its progression to HF is
compelling because of the enormous public health impact of
these conditions. Major gaps in knowledge include the
remainder of genomic and epigenetic cause of DCM, that
when discovered will not only enlarge our insight into the
pathways to the final DCM phenotype but will also aid the
discovery of additional genomic, proteomic, and metabolic
biomarkers to detect very early DCM and HF, inform
prognosis, and guide the development of novel therapeutics.
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